Resource Library
Showing 1 to 10 of 208 results
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a side effect that can happen after some forms of immunotherapy treatment. It may cause you to experience serious neurological symptoms.
Learn practical ways to be a proactive agent of change in your own cancer experience or that of your loved one. This webcast was led by Geoffrey Molle and Natasha Sani, from the Community Services Team at LLSC, and will include people impacted by blood cancer. They will offer tips and resources to participate in your own care decisions. Called “self…
Acute myeloid leukemia (AML): Expanding access to novel treatment and care, 2024 Leukemia Conference
Acute myeloid leukemia (AML) is a type of cancer that forms in blood cells and bone marrow that progresses rapidly if untreated. In this presentation, Dr. Brett Houston, a hematologist at the University of Manitoba, will speak about her work in clinical trials in finding ways to optimize care and improve outcomes for patients affected with acute leukemia,…
Acute lymphoblastic leukemia (ALL) affects immature white blood cells called lymphoblasts and can progresses quickly without treatment. Dr. Dawn Maze, a member of the Leukemia Program and the Elizabeth and Tony Comper MPN Program at the Princess Margaret Cancer Centre, addresses treatment of acute lymphoblastic leukemia, advances in research and management…
RNA is more than just DNA's lesser-known cousin. Dr. Katherine Borden, Professor, Pathology, Cell Biology at the Institute for Research in Immunology and Cancer, University of Montreal and Dr. Sarit Assouline, chief of the Division of Hematology at the JGH and Senior Investigator in the Lady Davis Institute at the JGH, unpack the scientific wonder that…
Chronic lymphocytic leukemia (CLL): Advances in research & treatment: 2024 Leukemia Conference, LLSC
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults and can vary from person to person. This is why a one-size-fits-all treatment approach is not optimal. Research advances in how we treat CLL are discussed by Dr. Anthea Peters, Hematologist at the Cross Cancer Institute in Edmonton, and Associate Professor, Department of…
Chronic myeloid leukemia (CML): Treatment options, minimizing side effects, 2024 Leukemia Conference
Chronic myeloid leukemia (CML) is a rare type of leukemia that can happen when cells that make the blood develop a genetic change called BCR-ABL1 (Philadelphia chromone). Dr. M. Lynn Savoie, hematologist at Tom Baker Cancer Centre in Calgary, Alberta, discusses treatment options, including hematopoiesis stem cell transplants, and ways to minimize side…
You or your loved one has been diagnosed with chronic myeloid leukemia (CML).This booklet was designed to answer some questions you may have about chronic myeloid leukemia (CML). It summarizes what CML is and its phases, as well as treatment options available in Canada and their side effects.
CML is a rare type of leukemia (about 15% of all new cases of leukemia are CML) that occurs when a person has a Philadelphia chromosome or another mutation which expresses a new gene (BCR-ABL) inside certain blood cells, causing the bone marrow cells to make too many white blood cells. The Philadelphia chromosome is present in 95% of people with CML, but it…
Graft vs Host Disease, known as GvHD, is a side effect of a life saving procedure. People who undergo an allogeneic stem cell transplant - when a donor's stem cells are transplanted into the recipient - can experience either acute or chronic GvHD. In this podcast, listen to blood cancer survivor Libby Goszer, who describes her experience living with…